M & a cooperation, cost reduction and image recovery Roche, BMS, Novartis and other new plans!

Compiling coco In January 2020, the annual J.P Morgan medical and health conference came, and pharmaceutical companies of all sizes tried their best to attract investors This year, as in the past few years, the pharmaceutical industry has lifted investors' appetite through pre conference trading announcements Incyte and Biogen announced on Monday that they have reached R & D cooperation worth US $750 million and US $75 million with MorphoSys and Pfizer respectively, involving projects of anti-CD19 antibody tafasitamab for B-cell lymphoma, sunset syndrome and Parkinson's disease for Alzheimer's disease Pf-05251749, a small molecule CK1 inhibitor for sleep disorders In addition, on the first day of J.P Morgan medical and Health Conference (13th), Johnson & Johnson, Novartis, Gilead, Roche and other large companies all appeared to release the latest progress What are their highlights? With the summary of fiercepharma website and Sina medicine, we can find out For many years, Johnson & Johnson has maintained its growth momentum, which is not expected to change in the short term The secret to growth? Jennifer Taubert, chairman of Johnson & Johnson's global pharmaceutical business, said recently that by 2023, about 75% of the company's revenue growth will come from existing drugs, whether through market share growth, new indications or early treatment plans to obtain regulatory approval In the face of the severe pricing environment of the whole industry, Johnson & Johnson has begun to rely on the growth of sales volume to get through the difficulties, and its diversified business portfolio can also provide enterprise stability for the "sudden storm" in any field After the approval of the second RNAi therapy by the US FDA, Alnylam plans to continue to attack in 2020 In the next 12-24 months, the company will add at least four new candidate drugs in the later stage, including lumisilan, a self-developed primary hyperoxaluria drug, vutrisiran, an attr amyloidosis drug, and inclisiran, a PCSK9 candidate drug, and fitusiran, a hemophilia drug Chief executive John maraganore said Monday that the prospect of givlaari, a new RNA therapy approved in November 2019 for acute porphyria, is promising to make Alnylam the top five biopharmaceutical company A closer look at the $5.1 billion partnership with Galapagos since July 2019 reveals some clues to Gilead's science strategy Daniel O'Day, CEO, said in his speech: we hope to find complementarities with Galapagos Of course, each deal cannot be as broad as the 10-year deal with Galapagos Investors also look forward to regular partnerships, including with SMEs O'Day assured investors that Geely would still make some direct acquisitions "The vast majority of deals are early stage projects, but companies are considering complementing their later stage portfolios," he said Novartis is no stranger to social scandals and is working to restore its reputation in 2020 In a report released this month, Novartis will launch a series of corporate goals aimed at improving the company's position in society, focusing on ethics, drug access, global health and corporate citizenship, said vas Narasimhan, chief executive of Novartis At the same time, set up a new executive team to follow up the progress of the goals It is understood that target performance will be linked to executive pay In addition to the promise of trust, Novartis also stressed its ambition in "digital" Now Novartis employs 1500 data scientists In order to achieve all the company's goals, Novartis must become a research and development "start-up machine" At present, the company has 15 ongoing or recent achievements On Monday, Novartis said it plans to conduct a large-scale clinical trial with the British government to test the preventive effect of the new heart disease drug inclisiran on people with high cardiovascular risk In December 2019, Novartis spent nearly $10 billion to acquire the medicines company, the original developer of inclisiran, and at the same time obtained the opportunity to cooperate with the British government in research and development Novartis has huge "ambitions" for the drug, saying it is expected to apply for European approval in the first three months of 2020 Like other large multinational pharmaceutical companies, Novartis has growth plans in China and is expected to obtain 50 drug regulatory approvals in China in the next five years Two years ago, K? Re Schultz, Teva's chief executive, told J.P Morgan health that the company's situation was dramatic The former star drug company looks shaky amid huge debts, market competition for the star drug Copaxone and a sharp drop in US generic prices But this year, Tyva is ready to report improvements The company has closed or sold 13 manufacturing plants, more than 10 are in the process of closing or selling, and 40 laboratories and offices For Schultz, the most important thing is to clean up the debt In the past two years, TIWA's debt has decreased by $8 billion So what is the company's plan for the next phase? Schultz said that it will optimize manufacturing, use the expertise of generic drugs to promote bio generic drugs, develop and expand Huntington's dance medicine austedo and migraine preventive medicine ajovy in China, which may soon make up for the loss of revenue caused by the continuous decline of Copaxone marketing At the conference, Roche and Illumina, a DNA sequencing company, signed a 15 year non exclusive cooperation agreement The two sides will jointly develop the whole cancer detection method of the latter as an auxiliary diagnosis for different cancer drugs In addition, Roche will choose to develop and manufacture genome test kits for tumor tissue and blood samples for Illumina's current and upcoming sequencing hardware product lines (such as nextseq 550dx and the upcoming novaseqdx system) Last year, the news that BMS intends to buy new base for $74 billion took the lead at J.P Morgan health conference A year later, just after the deal ended, the new CEO Giovanni caforio said, "the new base gives us better opportunities than when the news was announced The company is expected to meet its commitment to reduce costs by $2.5 billion by 2022 and about a third by 2020 alone " At present, BMS has made great progress in integration, leading the team in place, designed the operation mode of the new company, and made great progress in business and R & D However, the integration of it, finance and pricing processes and systems of the two companies is just beginning, and there is still a lot of work to be done in 2020 Although the start of the pharmaceutical investment circle in 2020 is not similar to that of last year, a report by experts from Ernst & Young shows that the remaining M & A activities this year should be as strong as last year, and biotechnology and medical technology may play a greater role this year In the current market, life science companies have the ability to provide transaction capital worth US $1.4 trillion, so there is no need to worry that the health care industry cannot afford large or active merger and acquisition events.